Sign in

Research summary ·

ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Endometrial Cancer: 2026 Update.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This is a 2026 update of imaging advice from the American College of Radiology. It covers endometrial cancer before treatment. It also covers follow-up after treatment. It is an evidence-based review of imaging options. A panel of experts reviews it each year. It draws on journal studies and expert opinion.

What they found

The abstract does not give study results. It lists scans that are usually appropriate in set cases. MRI of the pelvis is usually appropriate to judge local tumor spread. For aggressive types or suspected spread, other scans are usually appropriate. These are CT of the chest, abdomen and pelvis, and FDG-PET/CT.

What it means for patients

The guideline says routine imaging follow-up is usually not appropriate. This applies to patients with no symptoms after treated low- or intermediate-risk disease. It says CT may be appropriate in some high-risk patients with no symptoms. If cancer may have returned, it lists MRI, CT and FDG-PET/CT.

Why it is not certain yet

Where journal evidence is thin, experts may be the main source. The abstract says this itself. The ratings use methods adapted from GRADE and RAND. The abstract does not say how strong the evidence is for each point. It does not give the number of studies.

Source

ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Endometrial Cancer: 2026 Update.

PubMed · PMID 42955038

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Endometrial cancer publications